Parameter
| Biomarker | NLR | Full name | Neutrophil-Lymphocyte Ratio | Molecular Type | Cell Ratio |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Frontotemporal Dementia | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Whole Blood (Hematology Analyzer) | ||
| Pathobiological Mechanisms | A systemic inflammatory indicator; elevated in FTD due to microglial activation, reflecting progression risk. | ||||
| Clinical Availability Status | Clinically available (routine testing) | ||||
| Notes and Dynamics | The survival period of bvFTD patients with NLR >3.5 is 42% shorter than those with NLR <2, positively correlated with CSF IL-6. | ||||